{"nctId":"NCT02211209","briefTitle":"The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome","startDateStruct":{"date":"2014-12","type":"ACTUAL"},"conditions":["Familial Chylomicronemia Syndrome"],"count":67,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Volanesorsen","type":"EXPERIMENTAL","interventionNames":["Drug: Volanesorsen"]}],"interventions":[{"name":"Volanesorsen","otherNames":["ISIS 304801","ApoC-III","Approach","IONIS-APOCIIIRx"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of chylomicronemia\n* A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia)\n* Fasting triglycerides (TG) ≥ 750 mg/dL (8.4 mmol/L) at Screening\n\nExclusion Criteria:\n\n* Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%\n* Other types of severe hypertriglyceridemia\n* Active pancreatitis within 4 weeks of screening\n* Acute Coronary Syndrome within 6 months of screening\n* Major surgery within 3 months of screening\n* Treatment with Glybera therapy within 2 years of screening\n* Previous treatment with IONIS-APOCIIIRx\n* Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3","description":"The Month 3 endpoint was defined as the average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"-76.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Postprandial TG Area Under the Curve (AUC)(0-9h)","description":"Participants had 2 postprandial assessments - one at Baseline (completed at least 48 hours prior to first dose) and one at any time between Week 13 and 19, inclusive. Assessment timepoints include from 1-hr before to up to 9 hrs after ingestion of the meal at 1-hour interval. Postprandial AUC results were calculated using a linear trapezoidal rule for each postprandial measure in the subset of participants who had postprandial assessments 0-9 hour results at baseline and the postbaseline between Week 13 to 19.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.92","spread":"121.54"},{"groupId":"OG001","value":"-234.77","spread":"94.86"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting TG at Month 3","description":"The Month 3 endpoint was defined as the average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"-1712","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response Rate Defined as Participants With Fasting Plasma TG < 750 mg/dL at Month 3","description":"The Month 3 endpoint was defined as the average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments. mg/dL = milligrams per deciliter","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3","description":"The Month 3 endpoint was defined as the average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency and Severity of Participant-reported Abdominal Pain During the Treatment Period","description":"Abdominal pain was measured according to the Bracket electronic patient-reported outcomes (ePRO) assessment. Scores were categorized as follows: no pain (pain score: 0), mild (pain score: 1-3), moderate (pain score: 4-6), or severe (pain score: 7-10). The yearly frequency was calculated as the number of episodes during the on-treatment period / (last dose date - first dose date + 28) \\* 365.25. Missing data were imputed by using next observation carried back (NOCB) if there was a subsequent score available.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of the Composite of Episodes of Acute Pancreatitis and Participant-reported Moderate/Severe Abdominal Pain During the Treatment Period","description":"Moderate/severe abdominal pain was defined as having a pain score of 4-10 on the Bracket electronic patient-reported outcomes (ePRO) assessment. Scores were categorized as follows: no pain (pain score: 0), mild (pain score: 1-3), moderate (pain score: 4-6), or severe (pain score: 7-10). The yearly frequency was calculated as the number of episodes during the on-treatment period / (last dose date - first dose date + 28) \\* 365.25.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"4.28"},{"groupId":"OG001","value":"2.73","spread":"6.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hepatosplenomegaly as Assessed by MRI at Week 52","description":"The Week 52 endpoint was defined as the average of Week 50 (Day 344)/Week 51 (Day 351) and Week 52 (Day 358) fasting assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":33},"commonTop":["Injection site erythema","Injection site pain","Abdominal pain","Nasopharyngitis","Headache"]}}}